|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A comparison of Agiolax and lactulose in elderly patients with chronic constipation 显示文摘 | Passmore AP Davies KW Flanaqan PG | 1993 | Pharmacology1993，47，1： | 1 |
| 2 | Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials显示文摘 | Passmore AP Bayer A J Steinhagen-Thiessen E | 2005 | Journal of the neurological sciences2005，，： | 1 |
| 3 | Cause of death in Alzheimer's disease: a cohort study显示文摘 | Todd S Barr S Passmore AP | 2013 | QJM2013，106，8： | 1 |
| 4 | Digoxin toxicity in the aged: characterizing and avoiding the problem 显示文摘 | Passmore AP Johnston GD | 1991 | Drugs Aging1991，1，： | 1 |
| 5 | A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease显示文摘 | Patterson CE Passmore AP Crawford VL | 2004 | Int J Clin Pract2004，58，2： | 1 |
| 6 | Cognitive,global,and functional benefit of donepezil in Alzheimer's disease and vascular dementia:results from large-scale clinical trisls显示文摘 | Passmore AP Bayer AJ | 2005 | Neurol Sci2005，229，： | 1 |
| 7 | A comparison of Agiolaxand lactulose in elderly patients with chronic constipation 显示文摘 | Passmore AP Davies KW Flanaqan PG e( al | 1993 | Pharmacology1993，47，1： | 1 |
| 8 | Genetically increased risk of sleep disruption in Alzheimer's disease显示文摘 | Craig D Hart DJ Passmore AP | 2006 | Sleep2006，29，8： | 1 |
| 9 | The development of effective biomarkers for Alzheimer's disease:A review显示文摘 | Henry MS Passmore AP Todd S | 2013 | International Journal of Geriatric Psychiatry2013，28，7： | 1 |
| 10 | Cognitive, global, and functional benefit of donepezil in Alzheimer, s disease and vascular dementia: results from large-scale clinical trisls 显示文摘 | Passmore AP Bayer AJ Steinhagen TE | 2005 | NeurolSei2005，，： | 1 |
| 11 | Designing appropriate clinical trials to assess ACEI use and cognitive decline in older a- dults with hypertension 显示文摘 | Todd S McGuinness B Passmore AP | 2010 | Arch Intern Med2010，170，1： | 1 |
| 12 | Cognitive, global and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large- scale clinical trials 显示文摘 | Passmore AP Bayer A J Steinhagen- Thiessen E | 2005 | J Neurol Sci2005，1，： | 1 |
| 13 | Cognitive, global and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from largescale clinical trials 显示文摘 | Passmore AP Bayer A J Steinhagen-Tbiessen E | 2005 | J Neurol Sci2005，，： | 1 |
| 14 | Plasma chain-breaking antioxidants in Alzheimer'sdisease, vascular dementia and Parkinson's disease显示文摘 | Foy CJ Passmore AP Vahidassr MD | 1999 | QJM1999，92，1： | 1 |
| 15 | The development of effec- tive biomarkers for Alzheimer: disease: a review显示文摘 | Henry MS Passmore AP Todd S | 2013 | Int J Geriatr Psychiatry2013，28，4： | 1 |
| 16 | Cognitive,global, and functional benefits of donepezil in Alzhelmer's disease and vascular dementia: results from large scale clinical trials 显示文摘 | Passmore AP Bayer AJ Steinhagen-Thiessen E | 2005 | Neuro Sci2005，，： | 1 |
| 17 | Genetically increased risk of sleepdisruption in Alzheimer's disease显示文摘 | Graiq D Hart DJ Passmore AP | 2006 | Sleep2006，29，8： | 1 |
| 18 | Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials显示文摘 | Passmore AP Bayer AJ Steinhagen-Thiessen E | 2005 | J Neurol Sci2005，，： | 1 |
| 19 | Plasma chain-breaking antioxidants in Alzheimer's disease,vascular dementia and Parkinson's disease显示文摘 | Foy CJ Passmore AP Vahidassr MD | 1999 | QJM1999，92，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员